Conditions: Parkinson's Disease Psychosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 123
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.

Detailed description:

Arms:
arm 1: pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks arm 2: Placebo tablet, once daily by mouth, 6 weeks arm 3: pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks

Interventions: intervention 1: Pimavanserin tartrate (ACP-103) intervention 2: Pimavanserin tartrate (ACP-103) intervention 3: Pimavanserin tartrate (ACP-103)
Intervention descriptions: intervention 1: 10 mg, tablet, once daily by mouth, for six weeks intervention 2: 20 mg, tablet, once daily by mouth, for six weeks intervention 3: Placebo, tablet, once daily by mouth, for six weeks

Protocol document: